Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1179546817730322 http://scihub22266oqcxt.onion/10.1177/1179546817730322 C5606341!5606341!28951660     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Med+Insights+Cardiol 2017 ; 11 (ä): ä Nephropedia Template TP {{tp|p=28951660|t=2017. Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy |pdf=|usr=}}{{28951660}} gab.com Text Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy JO: Clin Med Insights Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=28951660 #FOAvip Background:: Transthyretin cardiomyopathy (TTR-CM) is a progressive, fatal disease caused by the accumulation of misfolded transthyretin (TTR) amyloid fibrils in the heart. Tafamidis is a kinetic stabilizer of TTR that inhibits misfolding and amyloid formation. Methods:: In this post hoc analysis, data from an observational study (Transthyretin Amyloidosis Cardiac Study; n?=?29) were compared with an open-label study of tafamidis in patients with TTR-CM (Fx1B-201; n?=?35). To ensure comparable baseline disease severity, patients with New York Heart Association (NYHA) functional classification ?III were excluded in this time-to-mortality analysis. Results:: Patients with either wild-type or Val122Ile genotypes treated with tafamidis have a significantly longer time to death compared with untreated patients (P?=?.0004). Similar results were obtained when limiting the analysis to wild-type patients only, without restricting NYHA functional classification (P?=?.0262). Conclusions:: These results support earlier conclusions suggesting that tafamidis slows disease progression compared with no treatment outside of standard of care and warrant further investigation. Trial Registration:: ClinicalTrials.gov, NCT00694161. Twit Text FOAVip Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy ????Clin Med Insights Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=28951660 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28951660 #FOAvip English Wikipedia <ref>{{Cite pmid|28951660}}</ref> Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy #MMPMID28951660 Sultan MB; Gundapaneni B; Schumacher J; Schwartz JH Clin Med Insights Cardiol 2017[]; 11 (ä): ä PMID28951660show ga Background:: Transthyretin cardiomyopathy (TTR-CM) is a progressive, fatal disease caused by the accumulation of misfolded transthyretin (TTR) amyloid fibrils in the heart. Tafamidis is a kinetic stabilizer of TTR that inhibits misfolding and amyloid formation. Methods:: In this post hoc analysis, data from an observational study (Transthyretin Amyloidosis Cardiac Study; n?=?29) were compared with an open-label study of tafamidis in patients with TTR-CM (Fx1B-201; n?=?35). To ensure comparable baseline disease severity, patients with New York Heart Association (NYHA) functional classification ?III were excluded in this time-to-mortality analysis. Results:: Patients with either wild-type or Val122Ile genotypes treated with tafamidis have a significantly longer time to death compared with untreated patients (P?=?.0004). Similar results were obtained when limiting the analysis to wild-type patients only, without restricting NYHA functional classification (P?=?.0262). Conclusions:: These results support earlier conclusions suggesting that tafamidis slows disease progression compared with no treatment outside of standard of care and warrant further investigation. Trial Registration:: ClinicalTrials.gov, NCT00694161. äTreatment With Tafamidis Slows Disease Progression in Early-Stage Tran(epmc).pdf DeepDyve Pubget Overpricing